These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 2713555)
21. Autologous bone marrow transplantation for acute lymphoblastic leukemia: role of bone marrow purging. Canals C; Picón M; Sanchez T; Torrico C; Amill B; Tugues D; Sierra J; Grañena A; Badell I; Brunet S Prog Clin Biol Res; 1994; 389():125-32. PubMed ID: 7700894 [No Abstract] [Full Text] [Related]
22. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Pfeiffer M; Stanojevic S; Feuchtinger T; Greil J; Handgretinger R; Barbin K; Jung G; Martin D; Niethammer D; Lang P Bone Marrow Transplant; 2005 Jul; 36(2):91-7. PubMed ID: 15908973 [TBL] [Abstract][Full Text] [Related]
23. [Use of monoclonal antibodies in acute lymphoblastic leukemia in children. I. Immunological subclassification of acute lymphoblastic leukemia]. Kołecki P; Radwańska U Pediatr Pol; 1988 Nov; 63(11):693-7. PubMed ID: 3253655 [No Abstract] [Full Text] [Related]
24. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463 [TBL] [Abstract][Full Text] [Related]
25. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. Uckun FM; Stong RC; Youle RJ; Vallera DA J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712 [TBL] [Abstract][Full Text] [Related]
26. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257 [TBL] [Abstract][Full Text] [Related]
27. Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Turzanski J; Daniels I; Haynes AP Br J Haematol; 2009 Apr; 145(1):137-40. PubMed ID: 19183195 [No Abstract] [Full Text] [Related]
28. Elimination of clonogenic leukemic cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Murakami S; Shimazaki C; Oku N; Itoh K; Takeda N; Fujita N; Ura Y; Nakagawa M Prog Clin Biol Res; 1990; 333():253-61. PubMed ID: 2308985 [No Abstract] [Full Text] [Related]
29. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550 [TBL] [Abstract][Full Text] [Related]
30. [Ex vivo purging methods for autologous bone marrow transplantation]. Kojima S; Ueda R Nihon Rinsho; 1990 Sep; 48(9):2117-24. PubMed ID: 2232217 [No Abstract] [Full Text] [Related]
33. Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study. Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A Hum Antibodies; 1997; 8(2):95-8. PubMed ID: 9289394 [TBL] [Abstract][Full Text] [Related]
34. Preliminary clinical trial of autologous bone marrow transplantation after in vitro monoclonal antibody and complement treatments in null cell-type acute lymphocytic leukemia. Morishima Y; Sao H; Ueda R; Morishita Y; Murase T; Kodera Y; Ohno R; Tahara T; Yoshikawa S; Kato Y Jpn J Cancer Res; 1985 Dec; 76(12):1222-9. PubMed ID: 3937834 [TBL] [Abstract][Full Text] [Related]
35. Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. Freedman AS; Takvorian T; Nadler LM; Anderson KC; Sallan SE; Ritz J Cancer Treat Res; 1988; 38():265-83. PubMed ID: 2908599 [No Abstract] [Full Text] [Related]
36. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Jándula BM; Nomdedeu J; Marín P; Vivancos P Bone Marrow Transplant; 2001 Jan; 27(2):225-7. PubMed ID: 11281397 [TBL] [Abstract][Full Text] [Related]
37. A direct and effective immunomagnetic method for bone marrow purging in non-T ALL malignancies. The use of an anti-HLA-DR antibody gives sustained engraftment. Wang MY; Fodstad O; Funderud S; Bengtsson M; Totterman T; Ludwig WD; Martin H; Kvalheim G Prog Clin Biol Res; 1994; 389():119-24. PubMed ID: 7700893 [No Abstract] [Full Text] [Related]
38. Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1. Kasai M; Akatsuka Y; Emi N; Taji H; Kohno A; Abe A; Tanimoto M; Kodera Y; Saito H Int J Hematol; 1999 Feb; 69(2):112-8. PubMed ID: 10071461 [TBL] [Abstract][Full Text] [Related]
39. Early relapse after rituximab chemoimmunotherapy. Kiss F; Buslig J; Szegedi I; Scholtz B; Kappelmayer J; Kiss C Pediatr Blood Cancer; 2008 Feb; 50(2):372-5. PubMed ID: 17973316 [TBL] [Abstract][Full Text] [Related]
40. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement. Grañena A; Castellsagué X; Badell I; Ferra C; Ortega J; Brunet S; Puntí C; Sureda A; Picón M; Valls A; Rutllant M; García J Bone Marrow Transplant; 1999 Sep; 24(6):621-7. PubMed ID: 10490727 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]